XTL Biopharmaceuticals (NASDAQ:XTLB – Get Free Report) and Crescent Biopharma (NASDAQ:CBIO – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership.
Analyst Ratings
This is a breakdown of current recommendations and price targets for XTL Biopharmaceuticals and Crescent Biopharma, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| XTL Biopharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
| Crescent Biopharma | 1 | 1 | 2 | 2 | 2.83 |
Crescent Biopharma has a consensus target price of $29.60, suggesting a potential upside of 75.25%. Given Crescent Biopharma’s stronger consensus rating and higher probable upside, analysts clearly believe Crescent Biopharma is more favorable than XTL Biopharmaceuticals.
Risk and Volatility
Profitability
This table compares XTL Biopharmaceuticals and Crescent Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| XTL Biopharmaceuticals | N/A | N/A | N/A |
| Crescent Biopharma | N/A | -101.50% | -86.86% |
Valuation & Earnings
This table compares XTL Biopharmaceuticals and Crescent Biopharma”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| XTL Biopharmaceuticals | $450,000.00 | 11.96 | -$6.97 million | ($0.64) | -3.55 |
| Crescent Biopharma | $10.84 million | 57.87 | -$153.94 million | ($6.72) | -2.51 |
XTL Biopharmaceuticals has higher earnings, but lower revenue than Crescent Biopharma. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
4.4% of XTL Biopharmaceuticals shares are held by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are held by institutional investors. 29.0% of XTL Biopharmaceuticals shares are held by company insiders. Comparatively, 24.8% of Crescent Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Crescent Biopharma beats XTL Biopharmaceuticals on 8 of the 14 factors compared between the two stocks.
About XTL Biopharmaceuticals
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.
About Crescent Biopharma
Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.
Receive News & Ratings for XTL Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XTL Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
